<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Clinical Laboratory Diagnostics</journal-id><journal-title-group><journal-title xml:lang="en">Russian Clinical Laboratory Diagnostics</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиническая лабораторная диагностика</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-2084</issn><issn publication-format="electronic">2412-1320</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">643406</article-id><article-id pub-id-type="doi">10.17816/cld643406</article-id><article-id pub-id-type="edn">PICRLH</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Antimicrobial activity of silver proteinate and its changes during storage</article-title><trans-title-group xml:lang="ru"><trans-title>Антимикробная активность серебра протеината и её изменения при хранении</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7972-5861</contrib-id><contrib-id contrib-id-type="spin">1609-1183</contrib-id><name-alternatives><name xml:lang="en"><surname>Kotelevets</surname><given-names>Elena P.</given-names></name><name xml:lang="ru"><surname>Котелевец</surname><given-names>Елена Петровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>kotelevetse@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9113-9184</contrib-id><contrib-id contrib-id-type="spin">9216-5887</contrib-id><name-alternatives><name xml:lang="en"><surname>Vorobyova</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Воробьева</surname><given-names>Ирина Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Biology), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. биол. наук, доцент</p></bio><email>francais64@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1258-9807</contrib-id><contrib-id contrib-id-type="spin">2895-7565</contrib-id><name-alternatives><name xml:lang="en"><surname>Kiryushin</surname><given-names>Valery A.</given-names></name><name xml:lang="ru"><surname>Кирюшин</surname><given-names>Валерий Анатольевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>v.kirushin@rzgmu.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Ryazan State Medical University</institution></aff><aff><institution xml:lang="ru">Рязанский государственный медицинский университет имени академика И.П. Павлова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-06-23" publication-format="electronic"><day>23</day><month>06</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-07-25" publication-format="electronic"><day>25</day><month>07</month><year>2025</year></pub-date><volume>69</volume><issue>11</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>336</fpage><lpage>342</lpage><history><date date-type="received" iso-8601-date="2024-12-25"><day>25</day><month>12</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-05-16"><day>16</day><month>05</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Kotelevets E.P., Vorobyova I.V., Kiryushin V.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Котелевец Е.П., Воробьева И.В., Кирюшин В.А.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Kotelevets E.P., Vorobyova I.V., Kiryushin V.A.</copyright-holder><copyright-holder xml:lang="ru">Котелевец Е.П., Воробьева И.В., Кирюшин В.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2028-07-27"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://kld-journal.fedlab.ru/0869-2084/article/view/643406">https://kld-journal.fedlab.ru/0869-2084/article/view/643406</self-uri><abstract xml:lang="en"><p><bold>Background:</bold><italic> </italic>In the context of the growing problem of antibiotic resistance, the selection of drugs with non-specific antimicrobial action is a relevant approach for treating upper respiratory tract infections. Silver protein, known for its antimicrobial properties, is used as an active ingredient in several medical formulations.</p> <p><bold>Aim:</bold><italic> </italic>The work aimed to assess the effect of storage duration and temperature on the antimicrobial activity of the pharmaceutical preparation with the International Nonproprietary Name silver protein.</p> <p><bold>Methods:</bold><italic> </italic>To conduct the experimental study, reference strains of <italic>Staphylococcus aureus</italic> (ATCC 6538), <italic>Escherichia coli</italic> (ATCC 25922), <italic>Pseudomonas aeruginosa</italic> (ATCC 9027), <italic>Bacillus cereus</italic> (ATCC 14579), and <italic>Candida albicans</italic> (ATCC 10231) were used as test cultures, along with silver protein solutions stored at 22 °C and 7 °C. Inoculations were performed from day 0 to day 75 at 7-day intervals. Antimicrobial efficacy was assessed by comparing the diameters (mm) of microbial growth inhibition zones throughout the experiment.</p> <p><bold>Results:</bold><italic> </italic>On day 30, the diameters of the inhibition zones were larger in the 7 °C group: <italic>S. aureus</italic> by 25.0% (<italic>p</italic> = 0.033), <italic>E. coli </italic>by 12.2% (<italic>p</italic> = 0.041), <italic>P. aeruginosa</italic> by 18.3% (<italic>p</italic> = 0.042), <italic>B. cereus</italic> by 10.0% (<italic>p</italic> = 0.005<italic>)</italic>, and <italic>C. albicans</italic> by 42.7% (<italic>p</italic> = 0.016). On days 37, 45, 53, 60, 68, and 75 of the study, the diameters of the inhibition zones for <italic>S. aureus</italic>, <italic>P. aeruginosa, B. cereus</italic>, and <italic>C. albicans</italic> remained unchanged (9, 8, 7, and 7 mm, respectively); for <italic>E. coli</italic>, on days 37, 45, 53, and 60, the diameters remained the same as on day 30 (8 mm), whereas on days 68 and 75 a decrease to 7 mm was observed (12.5%, <italic>p</italic> = 0.005).</p> <p><bold>Conclusion:</bold><italic> </italic>Keeping the solution at 7 °C for 30 days does not reduce its antimicrobial activity, making it possible to choose a convenient storage option for the working solution. Given the preservation of antimicrobial activity through day 75, silver protein can be recommended for treating superinfections and chronic forms of rhinosinusitis.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>На фоне проблемы антибиотикорезистентности выбор лекарственных средств с неспецифическим антимикробным действием является актуальным решением в лечении инфекций верхних дыхательных путей. Обладающий антимикробной активностью серебра протеинат находит применение в качестве активного действующего вещества медицинских препаратов.</p> <p><bold>Цель. </bold>Изучение влияния продолжительности и температуры хранения лекарственного препарата с международным непатентованным названием серебра протеинат на его антимикробную активность.</p> <p><bold>Материалы и методы.</bold> Для выполнения экспериментального исследования в качестве тест-культур были взяты эталонные штаммы <italic>Staphylococcus </italic><italic>aureus</italic> (ATCC 6538), <italic>Escherichia </italic><italic>coli</italic> (ATCC 25922), <italic>Pseudomonas aeruginosa</italic> (ATCC 9027), <italic>Bacillus cereus</italic> (ATCC 14579), <italic>Candida albicans</italic> (ATCC 10231), растворы серебра протеината, хранившиеся при 22 °С и 7 °С. Посевы выполняли с «нулевого» по 75-й дни с интервалом 7 дней. Изучение антимикробной эффективности проводили путём сравнения диаметров зон подавления роста микробных штаммов (мм) в динамике эксперимента.</p> <p><bold>Результаты.</bold> На 30-й день исследования диаметры зон подавления роста при 7 °С больше: у <italic>S. </italic><italic>aureus</italic> — на 25,0% (<italic>p</italic>=0,033), <italic>E. </italic><italic>coli —</italic> на 12,2% (<italic>p</italic>=0,041), <italic>P. aeruginosa —</italic> на 18,3% (<italic>p</italic>=0,042), <italic>B. cereus</italic> — на 10,0% (<italic>p</italic>=0,005<italic>)</italic>, <italic>C. albicans</italic> — на 42,7% (<italic>p</italic>=0,016). На 37, 45, 53, 60, 68 и 75-й дни исследования в отношении <italic>S. </italic><italic>aureus,</italic> <italic>P. aeruginosa, B. cereus</italic> и <italic>C. albicans</italic> диаметры не изменились (9, 8, 7 и 7 мм соответственно); <italic>E. </italic><italic>coli — </italic>на<italic> </italic>37, 45, 53, 60-й по отношению к 30-му дню исследования диаметры не изменились (8 мм), на 68 и 75-й дни отмечено уменьшение диаметров зон подавления роста до 7 мм (12,5%, <italic>p</italic>=0,005).</p> <p><bold>Заключение. </bold>Нахождение препарата при 7 °С в течение 30-ти дней не снижает его антимикробную активность, позволяя выбрать удобный вариант хранения рабочего раствора. Учитывая сохранение антимикробной активности серебра протеина до 75-го дня можно рекомендовать его применение при суперинфекции, а также в лечении хронических форм риносинуситов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>silver proteinate</kwd><kwd>antimicrobial activity</kwd><kwd>acute sinusitis</kwd><kwd>shelf life</kwd><kwd>storage temperature.</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>серебра протеинат</kwd><kwd>антимикробная активность</kwd><kwd>острый синусит</kwd><kwd>срок хранения</kwd><kwd>температура хранения</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Burmistrov VA, Zaikovsky VI, Burmistrov AV, et al. Comparative electron microscopic and microbiological examination of silver proteinate preparations. Siberian Scientific Medical Journal. 2018;38(4):30–36. (In Russ.) doi: 10.15372/SSMJ20180404</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Kiselyov B, Abdulkerimov HT, Terskova NE, Chaukina VA. Clinical efficacy of the drug 200 mg silver proteinate in the complex therapy of acute infectious rhinitis in children, which occurred as part of an acute respiratory infection. Russian Otorhinolaryngology. 2021;20(4):88–95. doi: 10.18692/1810-4800-2021-4-88-95</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Karpishchenko SA, Rodneva YuA, Ekushov KA. Improving the clinical effectiveness of the treatment of acute inflammatory diseases of the upper respiratory tract in children with the use of silver-based medicines. Medical Council. 2022;(19):42–52. doi: 10.21518/2079-701X-2022-16-19-42-52</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gurov AV, Ermolaev AG, Dubovaya TK, et al. Current possibilities of using silver proteinate in the treatment of inflammatory diseases of the nose and paranasal sinuses. Medical Council. 2023;(7):46–51. doi: 10.21518/ms2023-120</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Wise SK, Lin SY, Toskala E. International consensus statement on allergy and rhinology: allergic rhinitis—executive summary. Int Forum Allergy Rhinol. 2018;8(2):85–107. doi: 10.1002/alr.22070</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: Allergic rhinitis – 2023. Int Forum Allergy Rhinol. 2023;13(4):293–859. doi: 10.1002/alr.23090</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Khina AG, Krutyakov YuA. Similarities and differences in the mechanism of antibacterial action of silver ions and nanoparticles. Applied Biochemistry and Microbiology. 2021;57(6):523–535. doi: 10.31857/S0555109921060052</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213–739. doi: 10.1002/alr.22741</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Cheng M, Dai Q, Liu Z, et al. New progress in pediatric allergic rhinitis. Front. Immunol. 2024;15:1452410. doi: 10.3389/fimmu.2024.1452410</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Wang J, Zhang Y, Chen Y, et al. Risk factors investigation for different outcomes between unilateral and bilateral chronic rhinosinusitis with nasal polyps patients. Clin Transl Allergy. 2024;14(9):e12395. doi: 10.1002/clt2.12395</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Zaitoun F, Al Hameli H, Karam M, et al. Management of Allergic Rhinitis in the United Arab Emirates: Expert Consensus Recommendations on Allergen Immunotherapy. Cureus. 2024;16(7):e65260. doi: 10.7759/cureus.65260</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Norman G, Christie J, Liu Z, et al. Antiseptics for burns. Cochrane Database Syst Rev. 2017;7(7):CD011821. doi: 10.1002/14651858.CD011821.pub2</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Fung MC, Bowen DL. Silver products for medical indications: risk-benefit assessment. J Toxicol Clin Toxicol. 1996;34(1):119–26. doi: 10.3109/15563659609020246</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Yan X, He B, Liu L, et al. Antibacterial mechanism of silver nanoparticles in Pseudomonas aeruginosa: proteomics approach. Metallomics. 2018;10(4):557–564. doi: 10.1039/c7mt00328e</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Slawson RM, Lohmeier-Vogel EM, Lee H, Trevors JT. Silver resistance in Pseudomonas stutzeri. Biometals. 1994;7:30–40. doi: 10.1007/BF00205191</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Liao S, Zhang Y, Pan X, et al. Antibacterial activity and mechanism of silver nanoparticles against multidrug-resistant Pseudomonas aeruginosa. Int J Nanomedicine. 2019;14:1469–1487. doi: 10.2147/IJN.S191340</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Jung WK, Koo HC, Kim KW, et al. Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli. Appl Environ Microbiol. 2008;74(7):2171–2178. doi: 10.1128/aem.02001-07</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Morones-Ramirez JR, Winkler JA, Spina CS, Collins JJ. Silver Enhances Antibiotic Activity Against Gram-Negative Bacteria. Sci Transl Med. 2013;5(190):190ra81. doi: 10.1126/scitranslmed.3006276</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Rugerio-Vargas C, Hurtado MM. Modification of the Silver Proteinate Impregnation Technique for Protozoa and Cultured Nerve Cells. Biotechnic &amp; Histochemistry. 1991;66(3):131–135. doi: 10.3109/10520299109110566</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Bozhkova SA, Gordina EM, Markov MA, et al. The Effect of Vancomycin and Silver Combination on the Duration of Antibacterial Activity of Bone Cement and Methicillin-Resistant Staphylococcus aureus Biofilm Formation. Traumatology and Orthopedics of Russia. 2021;27(2):54–64. doi: 10.21823/2311-2905-2021-27-2-54-64</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Xu L, Wang YY, Huang J, et al. Silver nanoparticles: Synthesis, medical applications and biosafety. Theranostics. 2020;10(20):8996–9031. doi: 10.7150/thno.45413</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Abdalla SSI, Katas H, Azmi F, et al. Antibacterial and Anti-Biofilm Biosynthesised Silver and Gold Nanoparticles for Medical Applications: Mechanism of Action, Toxicity and Current Status. Curr Drug Deliv. 2020;17(2):88–100. doi: 10.2174/1567201817666191227094334</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Hempelmann E, Krafts K. The mechanism of silver staining of proteins separated by SDS polyacrylamide gel electrophoresis. Biotech Histochem. 2017;92(2):79–85. doi: 10.1080/10520295.2016.1265149</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Wong AYH, Xie S, Tang BZ, Chen S. Fluorescent Silver Staining of Proteins in Polyacrylamide Gels. J Vis Exp. 2019;(146). doi: 10.3791/58669-v</mixed-citation></ref></ref-list></back></article>
